Disruption to 2D/3D Download CAD Requests

We're publishing improvements to our software for downloading CAD models. You can still request CAD models by using our web form and a representative will deliver your requested file formats. We apologize for any inconvenience. 

of

Disruption to 2D/3D Download CAD Requests
  • Find a Distributor

Online Tools

Close
PRODUCT SPECIFIER Determine coupling types for use in your particular project
CAD Downloads Download CAD drawings of specific couplings to use directly in your design software
    Product Catalogs Use of our product catalogs to view our complete product list

    Product Catalog (pdf)

    Right chevron

    View all Catalogs

    Right chevron

    Request a printed copy of our catalog. If you are distributor, please click here to order in bulk.

    Product Catalogs

    Sterile Connectors for Biosimilar Production

    Starting with Biologics

    Biosimilars are remarkably similar to an already-approved biologic, often called the “reference” product.  Like their biologic predecessor, biosimilars are most often large-molecule drugs derived from living organisms such as humans, animals, microorganisms or yeast. Biosimilar manufacturing begins when the reference product’s patent expires, with research and development starting sometimes three to five years earlier.

    Biosimilars Greatest Potential

    • Shorten time to market
    • Greater competition
    • Increased patient access
    • Lower patient treatment costs

    Biosimilars Boost Promise of Reduced Drug Acquisition Costs 

    Data must show that a biosimilar product is “highly similar” to the approved reference biologic product. With a shorter approval process, bioprocessing companies use the data already established by the reference―saving time, resources and unnecessary duplication of animal testing or expensive human clinical trials. However, there are still costs and time involved in ensuring the biosimilar has no clinically meaningful differences in safety, purity and potency from the reference product.

    Annualized savings from biosimilars reached $6.5B in the second quarter  of 2020, and savings are modeled to exceed $100 billion in aggregate over the next five years. 

    IQVIA Institute Report (2020) Biosimilars in the United States 2020 – 2024

    Small Changes Lead to Biosimilar Production Success

    The complexity and sophistication of manufacturing of the original biologic also apply to the biosimilar. While comparable, biosimilars have their own set of manufacturing challenges. Biosimilars are created from modifications to the manufacturing process that closely resembles the reference biologic. These changes in the manufacturing process can affect the safety, efficacy, or potency of the biosimilar. With the promise of lowering drug acquisition prices, operational costs become a key challenge for manufacturing biosimilars.

    Scalable, Faster, Efficient Biosimilar Processes

    To help compete on price, biosimilar manufacturers must develop highly efficient upstream, downstream, cold chain and fill-and-finish processes to reduce the overall cost of goods while ensuring the reliability of the biosimilar. Media transfer management plays a large part in biosimilar production, helping not only reduce costs but optimize the safe handling of the media.

    Using CPC Sterile Connectors in Meeting Biosimilar Production Challenges

    CPC sterile connectors are a critical component to bring together single-use assemblies while maintaining a sterile fluid pathway. They are precision-engineered to connect one processing stream to another―such as a container to a sampling line, media to a vessel or a filtration process to a filling line.

    CPC single-use aseptic connectors are a flexible, efficient and effective method to allow media to enter or leave a system flow path. The robust, easy-to-use design of the AseptiQuik® portfolio of sterile connectors prevents unwarranted material exchange between the process and the environment.

    Seven Reasons for Choosing AseptiQuik Sterile Connectors

    1. Prevent process contamination
    2. Maintain sterility
    3. Increase application design flexibility
    4. Offer a broad portfolio of configuration and size options
    5. Streamline inventory requirements
    6. Streamline inventory requirements
    7. Manufactured by company with extensive experience

    Aspetic-Genderless-Connectors

    CPC’s Skilled Team Focused on Bioprocessing

    CPC’s bioprocessing engineers are deeply familiar with the biosimilar production and their impact on media transfer in a single-use, hybrid or stainless-steel production system. With a strong emphasis on collaboration, our team works with your biosimilar processing experts to determine the best media handling connection solutions to maintain the highest quality, assure sterility, and deliver reliability. Our team, including materials scientists, design engineers and applications engineers, exclusively focuses on bioprocessing connectors, resulting in a robust portfolio of genderless, sterile and steam-in-place connectors and disconnects expressly for biosimilar production.

    Check Out the Latest Biopharma Technologies

    White paper page preview How Single-Use Connectors Advance Aseptic Processing

    Today’s market demand on biologic and pharmaceutical manufacturers to develop new drugs — combined with the economic environment — is challenging bioprocesses to review their processing systems and seek ways to make them more flexible, reliable and cost effective.

    Back to Top